Clinical efficacy of apatinib in treating refractory triple-negative advanced breast cancer
10.3969/j.issn.1000-8179.2017.15.643
- VernacularTitle:阿帕替尼治疗晚期难治性三阴性乳腺癌的临床疗效观察
- Author:
Xiaorui WANG
;
Xu WANG
;
Yehui SHI
;
Chen WANG
;
Zhongsheng TONG
- Keywords:
breast cancer;
molecular targeted therapy;
apatinib;
metastasis
- From:
Chinese Journal of Clinical Oncology
2017;44(15):769-772
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the effectiveness and safety of using apatinib in the treatment of refractory triple-negative advanced breast cancer. Methods:Eight cases of advanced triple-negative breast cancer patients confirmed via histopathology, who were previously treated with anthracycline, taxane, gemcitabine, capecitabine, and 500 mg/d apatinib in our hospital from July 2015 to November 2016, were retrospectively analyzed. The time of disease progress, effective rate, clinical benefits, and side effects were observed. Results:Eight patients were administrated with an average of 4 treatment cycles, and the effects were evaluated after 2 weeks. Four patients exhibited partial remission, 3 had a stable disease, and 1 had a progressive disease. The disease control rate was 87.5%, and the median progression free survival was 4.2 months. The main side effects were hand-foot syndrome (3/8), bone marrow arrest (4/8), hypertension (2/8), proteinuria (3/8), hemoptysis (1/8), nausea (2/8), and fatigue (2/8). Most of these side effects were tolerable. Conclusion:Apatinib can effectively and tolerably prolong survival time and improve the quality of life of patients with advanced triple-negative breast cancer.
